Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis
NCT06058156Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Nov 2023
- Primary completion
- Oct 2025
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of SAR444656 in atopic dermatitis (AD) (4 arms), sponsored by Sanofi. Primary endpoint: Percent Change From Baseline in Eczema Area and Severity Index at 16 weeks. Started Nov 2023; status: terminated.
02
Drugs
SAR444656
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06058156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06058156.